August 4, 2021 7:40am
Earnings’ releases today: Ionis Pharmaceuticals (IONS), Vericel (VCEL), MiMedx (MDXG), AxoGen (AXGN), and Editas Medicine (EDIT)
Pre-open indications: 1 Maintain SELL: BSTG
My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session
There is no breadline for fact and numbers-based share pricing intelligence!
Dow futures are DOWN -0.14% (-48 points), S&P futures are DOWN -0.10% (-4 points) and NASDAQ futures are barely UP +0.01% (+13 points)
Stock futures were mixed and fluctuating to the negative in Wednesday’s pre-open,
European markets advanced,
Asia-Pacific markets advanced, with the exception of Japan, as a private survey showed Chinese services activity growth accelerating in July. However, the rapid rise in Covid-19 infections throughout the region is keeping optimism contained.
Data Docket: employment data being released by ADP
Henry’omics:
Lower bonds yield has tended to set a more bearish tone for equities, by triggering concerns about the pace of the economic comeback.
Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542
Net Income:
- CRISPR Therapeutics (CRSP);
- uniQure NV (QURE);
Net losses:
- Ultragenyx Pharmaceuticals (RARE);
- Verastem (VSTM)
- Alnylam Pharmaceuticals (ALNY);
- Sage Therapeutics (SAGE);
- Global Blood Therapeutics (GBT)
- MiMedx (MDXG)
- Ionis Pharmaceuticals (IONS) – today;
- Editas Medicine (EDIT) - today;
Tuesday’s evening’s recap: “RegMed Investors’ (RMi) closing bell: the sector just can’t keep the upside candle lit” … https://www.regmedinvestors.com/articles/12032
- The Nasdaq closed UP +80.23 points (+0.55%);
- The IBB closed up +2.14% and XBI closed up +0.72%;
- Sector volume was LOW with 3 of the 10-upside having higher than the 3-month average volume with very LOW volume of 2 of 23-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was down -1.42 points or -7.30% at 18.04;
- Tuesday’s percentage (%) of the 10-upside were +0.28% (RGNX) to +4.22% (MESO) while the 23-downside ranges from -0.15% (CLLS) to -10.28% (VSTM);
Q3/21:
August: 1 positive and 1 negative close
July: 6 positives, 1 holiday and 15 negative closes
Q2/21:
- June: 15 positive and 8 negative closes
- May: 8 positive, 12 negative closes and 1 holiday
- April: 11 negative and 10 positive closes
Q1/21:
- March: 10 positive, 12 negative and 1 neutral closes
- February: 9 positive, 10 negative closes and 1 holiday
- January: 10 positive, 9 negative closes and 1 holiday
Companies in my headlights – It’s your decision; I provide an idea and context:
The Biostage (BSTG) Chronicles - Maintaining Sell – Could the share price stay up if it wasn’t being “pumped”?
Biostage (BSTG) closed flat with 616 shares traded after Monday’s -$0.05 to $1.60 with 571 shares traded.
Question#1: WHAT is the end game or play-book for this company, it has NOT done ANYTHING to monetize their asset of an approved IND with NO clinical trial initiative … so WHERE and WHAT is the value proposition?
Open ended Question#2: WHAT is the status of the $404,221.00 PPP Loan? Referencing the loan agreement, “In the event that any portion of the PPP Loan is not forgiven in accordance with the PPP, following a six-month deferred period that ends November 4, 2020, the Company will be required to pay the Bank monthly payments of principal and interest to repay the PPP Loan in full on or before the maturity date.”
MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.
Morning Indications: passing on the session – too many factors!
Earnings preview:
Intellia Therapeutics (NTLA) reports Thursday and is expected to deliver flat earnings compared to the year-ago quarter on lower revenues when it reports results for the quarter ended June 2021. EDIT is projected to report earnings of -$0.61 per share, which would represent no growth from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $12.03 million, down 26.03% from the year-ago period. NTLA's full-year Zacks Consensus Estimates are calling for earnings of -$2.56 per share and revenue of $36.32 million. These results would represent year-over-year changes of -6.67% and -37.37%.
The BOTTOM LINE: Earnings continued to guide sector sentiment … this week after eight (8) releases to date …
Q2 earnings potential LPS (loss-per-share) later this week:
- Brainstorm Cell Therapeutics (BCLI) and Intellia therapeutics (NTLA) on Thursday,8/5]
- Cellectis SA (CLLS) on Friday, 8/6
Remember: Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out.
Risk is no doubt increasing as we head into the troublesome August and September months
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
My motto, never leave an investor uninformed about what I know!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
